Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505982 | 0.88 | MAOB (0.46) | MAOBGAA | |
| SCHEMBL3504313 | 0.87 | MAOB (0.44) | MAOBGAA | |
| SCHEMBL7298728 | 0.83 | MAOB (0.42) | MAOBGAA | |
| SCHEMBL3505301 | 0.83 | MAOB (0.42) | MAOBGAA | |
| SCHEMBL3506406 | 0.82 | MAOB (0.43) | MAOBGAA | |
| SCHEMBL7300033 | 0.82 | MAOB (0.43) | MAOBGAA | |
| SCHEMBL7302420 | 0.80 | GAA (0.46) | MAOBGAA | |
| SCHEMBL3503050 | 0.79 | MAOB (0.38) | MAOBMGAT2 | |
| SCHEMBL7297318 | 0.79 | MAOB (0.71) | MAOB | |
| SCHEMBL3505978 | 0.78 | MAOB (0.38) | MAOBMGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110067123-A1 | MAO-B ELEVATION AS AN EARLY PARKINSON'S DISEASE BIOMARKER | BUCK INSTITUTE FOR AGE RESEARCH | 2011-03-17 | — | — | US | claimed |
| WO-2009105481-A1 | MAO-B ELEVATION AS AN EARLY PARKINSON'S DISEASE BIOMARKER | THE BUCK INSTITUTE FOR AGE RESEARCH (US) | 2009-08-27 | — | — | WO | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| EP-0655445-B1 | 1,3,4-oxadiazol-2(3H)-one Derivates, their preparation and their use as monoamine oxidase inhibitors | SYNTHELABO (FR) | 1997-08-27 | — | — | EP | claimed |
| US-5525619-A | INHIBITORS OF MONOAMINE OXIDASE B | SYNTHELABO (FR) | 1996-06-11 | — | — | US | claimed |
| EP-0655445-A1 | 1,3,4-oxadiazol-2(3H)-one Derivates, their preparation and their use as monoamine oxidase inhibitors | SYNTHELABO (FR) | 1995-05-31 | — | — | EP | claimed |
| JP-7196636-A | — | — | None | — | — | JP | disclosed |
| EP-3170499-A1 | TREATMENT FOR COCAINE ADDICTION | Tonix Pharmaceuticals, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-2611440-B1 | TREATMENT FOR COCAINE ADDICTION | TONIX PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2611440-A1 | TREATMENT FOR COCAINE ADDICTION | Tonix Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8481599-B2 | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism | TONIX PHARMACEUTICALS INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130165511-A1 | TREATMENT FOR COCAINE ADDICTION | TONIX Pharmaceuticals Holding Corp (US) | 2013-06-27 | — | — | US | disclosed |
| US-20030087814-A1 | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism | KRELE PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6476279-B2 | REACTING A HALOGENATED ALKANE WITH AN ALKYL VINYL ETHER TO FORM A HALOGENATED UNSATURATED ALDEHYDE, WHICH IS REDUCED TO FORM A HALOGENATED UNSATURATED ALCOHOL, WHICH IS FURTHER REDUCED | HONEYWELL INTERNATIONAL INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020095059-A1 | Reacting a halogenated alkane with an alkyl vinyl ether to form a halogenated unsaturated aldehyde, which is reduced to form a halogenated unsaturated alcohol, which is further reduced | HONEYWELL INTERNATIONAL, INC. | 2002-07-18 | — | — | US | disclosed |
| EP-0655445-B1 | 1,3,4-oxadiazol-2(3H)-one Derivates, their preparation and their use as monoamine oxidase inhibitors | SYNTHELABO (FR) | 1997-08-27 | — | — | EP | disclosed |
| US-5525619-A | INHIBITORS OF MONOAMINE OXIDASE B | SYNTHELABO (FR) | 1996-06-11 | — | — | US | disclosed |
| JP-H07196636-A | 1,3,4-OXADIAZOL-2(3H)-ONE DERIVATIVE AND MEDICINE CONTAINING THE SAME | SYNTHELABO SA | 1995-08-01 | — | — | JP | disclosed |
| EP-0655445-A1 | 1,3,4-oxadiazol-2(3H)-one Derivates, their preparation and their use as monoamine oxidase inhibitors | SYNTHELABO (FR) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885GAA 142/4885MGAT2 1962/4885 |
| US-20020095059-A1 | Reacting a halogenated alkane with an alkyl vinyl ether to form a halogenated unsaturated aldehyde, which is reduced to form a halogenated unsaturated alcohol, which is further reduced | ADH1A, ADH1C, ADH5 | MAOB 336/4885GAA 1913/4885MGAT2 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.